Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$5.50 USD
-0.24 (-4.18%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.61 +0.11 (2.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Coya Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
COYA 5.50 -0.24(-4.18%)
Will COYA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COYA
Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
Other News for COYA
COYA forms 180 Bearish Setup on September 20
Is COYA ready to move higher? Stochastic Buy Signal shows up after rocketing 6.1%
Lower Bollinger Band Walk appears for COYA after 4.59% move
Coya Therapeutics, Inc. (COYA) Gets a Buy from Lake Street
COYA: Analyst Jason Kolbert Maintains 'Buy' Rating with $18 Target | COYA Stock News